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A
 
BSTRACT
 
Respiratory syncytial virus (RSV) infection in early child-
hood is a risk factor for the development of wheezing,
significant decreases in pulmonary function and
increases in airway reactivity. Respiratory syncytial
virus infection also exacerbates recurrent wheezing
attacks in patients with established asthma. Here we
review the present understanding of RSV-induced
bronchial asthma, especially concerning the role of
eosinophils. Recent evidence suggests that eosinophils
are important in RSV infection and RSV-induced
asthma. For example, the eosinophil count and
concentrations of eosinophil cationic protein, an
eosinophil toxic granule protein, were elevated in
samples of blood and nasopharyngeal secretions from
patients with RSV infection or RSV-induced asthma; this
suggests that eosinophils degranulate in the respira-
tory tract during RSV infection. Respiratory syncytial
virus can infect human eosinophils, which produce
chemokines such as RANTES, monocyte chemotactic
protein-1 and macrophage inflammatory protein-1
 
α
 
.
We have demonstrated that RSV enhances superoxide
production by human eosinophils stimulated with a
lipid mediator, such as platelet-activating factor.
This response is dependent on 
 
β
 
2 integrin, 
 
α
 
M
 
β
 
2,
which is critical for eosinophil effector functions. Pre-
vious studies have demonstrated that RSV-infected
epithelial cells produce multiple cytokines and chem-
okines. We have found that RSV enhances eosinophil
adhesion and degranulation following infection of
BEAS-2B bronchial epithelial cells and that another
eosinophil toxic granule protein, major basic protein
or eosinophil peroxidase, synergistically augments
RSV-induced epithelial cell damage and apoptosis in
A549 cells. These results suggest that eosinophils and
their products enhance RSV-induced airway inflamma-
tion in asthma. Closely delineating the mechanism by
which RSV enhances eosinophilic inflammation in
asthma should be useful in devising more effective
therapy.
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In infants and young children, respiratory syncytial virus
(RSV) is a leading cause of serious upper and lower
respiratory tract infection, including acute bronchio-
litis.
 
1–3
 
 Respiratory syncytial virus accounts for 125 000
hospitalizations and 450 deaths annually in the US.
 
4
 
Annual epidemics occur from November to April, and
virtually all infants are infected by the age of 2 years.
Because immunity is not durable, reinfection occurs
throughout life, although subsequent infections are
nearly always mild. In a series of epidemiologic studies
of respiratory infections (the Tecumseh Studies), 20% of
children of aged 5–9 years had documented RSV
infections over the course of 1 year; this rate fell to 10%
in children aged 15–19 years and was approximately
5% in adults aged 20–50 years.
 
4
 
The recently developed human recombinant mono-
clonal antibody preparation palivizumab (Synagis
 
®
 
;
Abbott Laboratories, Abbott Park, IL, USA), significantly
lowers infection rates but is very costly. Because of the
highly infectious character of RSV, the ultimate solution to
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annual RSV epidemics remains the development of an
effective vaccine; however, attainment of this goal
remains far in the future. Longitudinal studies in adults5
and children6,7 have shown that 80–90% of common
colds are associated with asthmatic symptoms; specific
diagnosis of infections with rhino, parainfluenza and
influenza viruses, as well as RSV, were associated with
objective evidence of exacerbation of asthma. The most
frequently noted sequelae of RSV infection is persistant
wheezing associated with increased airway hyper-
reactivity in atopic asthma. Although this link has been
observed in one form or another for approximately
30 years, it remains a highly controversial subject. A
number of studies appear to have established at least a
statistical connection between severe lower respiratory
tract RSV infection and asthma in young children.2,8–11
Because the precise pathogenesis of asthma is not well
understood, much of the confusion concerning the link to
RSV arises from complex relationships between wheezing,
atopy and asthma, particularly in infants and young chil-
dren. In later life, RSV bronchiolitis appears unlikely to be
a cause of atopic asthma. The events and factors relating
RSV infection to asthma are summarized in Fig. 1. The
present review will focus on the mechanisms of RSV-
induced asthma, especially those involving eosinophils.
MECHANISMS OF RSV-INDUCED ASTHMA
Relationships between RSV infection and 
eosinophils
Various inflammatory cells, including bronchial epithelial
cells, lymphocytes, monocytes and neutrophils, are
involved in RSV infection and RSV-induced asthma.
Recent evidence suggests that eosinophils are also
important in RSV infection and asthma.1–3 However,
some studies point in other directions; for example,
bronchoalveolar lavage fluid (BALF) from intubated
infants with RSV bronchioltis was found to contain
predominantly neutrophils and lymphocytes rather than
eosinophils.12 Histopathologically, in RSV infection the
airways show infiltration by neutrophils and mono-
nuclear cells.13 Thus, eosinophils are not conspicuous in
RSV bronchiolitis. Nonetheless, much evidence impli-
cates eosinophils in allergic diseases and asthma gener-
ally, as well as in broncholitis and RSV-induced asthma.
Fig. 1 Respiratory syncytial virus (RSV) infection induces development and exacerbation of asthma. Respiratory syncytial virus infec-
tion is associated with persistent wheezing and increased airway hyperreactivity in atopic asthma. Although RSV bronchiolitis seems
unlikely to be a cause of atopic asthma in later life, RSV infection in early life, together with an atopic state, an atopic family history
and eosinophilia, may induce asthma development. BHR, bronchial hyperresponsiveness.
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In general, eosinophils play pivotal roles in allergic
diseases, such as bronchial asthma and allergic derma-
titis, and in parasitic infection.14–16 In inflammatory con-
ditions, eosinophils are induced to migrate from the
bloodstream into extravascular spaces by various medi-
ators released by T cells, mast cells and other inflamma-
tory cells. During this translocation, eosinophils tether to,
roll upon and firmly adhere to vascular endothelial cells
by binding to adhesion molecules such as selectins,16
β4 integrins and β2 integrins.17 Eosinophils then release
cytotoxic granule proteins and superoxide anion in
response to various stimuli, resulting in tissue damage at
inflammatory sites (Fig. 2).16
Several reports specifically link eosinophils to RSV
infections. For example, concentrations of eosinophil cat-
ionic protein (ECP), which is released from toxic granules
of eosinophils, were significantly higher in children with
RSV bronchiolitis than in children with RSV-induced upper
respiratory tract and lower respiratory tract disease not
involoving wheezing.18 Children with RSV bronchiolitis
had significantly higher serum ECP concentrations than
those with non-RSV diseases, whereas total eosinophil
counts were significantly decreased in all patients with
acute bronchiolitis.19 Furthermore, in RSV-infected chil-
dren with asthma, eosinophil counts in nasopharyngeal
secretions were higher in patients with the most severe
attacks, whereas younger patients had more eosinophils
in their nasopharyngeal secretions than older patients.
These trends were not found in influenza A virus patients
with asthma, suggesting that, in comparison with influ-
enza A virus-induced asthmatic attacks, RSV infection was
more likely to be associated with exacerbation of asthma
in infants and younger children while also inducing more
severe attacks.20 Apparently, then, in the respiratory tract,
eosinophil degranulation occurring during RSV infection
may participate significantly in the development of airway
obstruction and clinical asthmatic attacks. Furthermore, a
recent study has demonstrated that interleukin (IL)-5 and
interferon (IFN)-γ ratios were significantly increased in
BALF from asthmatic patients with or without identifiable
RSV infection compared with values in a control group.21
When infants in the bronchiolitis group were divided into
those with eosinophil-positive and eosinophil-negative
BALF, the eosinophil-positive subgroup had significantly
higher IL-5 and IL-5/IFN-γ ratios than in the control
group, whereas similar cytokine responses were not
induced in the eosinophil-negative subgroup. The
percentage of BALF eosinophils correlated significantly
with BALF IL-5 in both the asthmatic group and the
bronchiolitis group. These findings suggest that a sub-
group of patients with RSV-induced bronchiolitis shows
a T helper (Th) 2-type response, which could provide
a valuable framework for explaining the link between
RSV-induced bronchiolitis and asthma.21
A connection between eosinophils in RSV infection
and asthma was also supported by findings in a mouse
model. Respiratory syncytial virus infection resulted in
airway hyperresponsiveness in the acute phase and led to
Fig. 2 Effects of respiratory syncytial virus (RSV) infection on
the induction of cytokines and activation of inflammatory cells.
Eosinophils are induced to migrate from the bloodstream into
extravascular spaces by various mediators released by T cells,
mast cells and other inflammatory cells. During these processes,
eosinophils tether to, roll upon and firmly adhere to vascular
endothelial cells through binding to adhesion molecules, such
as selectins, 
 
β
 
4 integrins and 
 
β
 
2 integrins. Eosinophils then
release cytotoxic granule proteins and superoxide anion in
response to various stimuli, resulting in tissue damage at inflam-
matory sites. Respiratory syncytial virus infects various airway
cells, including epithelial cells, macrophages, lymphocytes and
eosinophils. Infection with RSV induces cytokine production by
these cells. The cytokines, in turn, can activate cells to promote
inflammation. ICAM-1, intercellular adhesion molecule-1;
VCAM-1, vascular cell adhesion molecule-1.
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changes in immune function likely to enhance the effects
of airway sensitization to antigen after infection. In both
situations, airway hyperresponsiveness was closely asso-
ciated with pulmonary eosinophilic inflammation.
 
22
 
Respiratory syncytial virus infection resulted in airway
eosinophilia and airway hyperresponsiveness in both
IL-4- and IFN-
 
γ
 
-deficient mice, but not in IL-5-deficient
mice.
 
23
 
 Reconstitution of IL-5-deficient mice with exo-
geous IL-5 restored these responses and enhanced the
responses in IL-4-deficient mice. Treatment with anti-very
late antigen (VLA)-4 prevented lung eosinophilia and
airway hyperresponsiveness following RSV infection and
IL-5 reconstitution. These results suggest that, in the
response to RSV, IL-5 is essential for influx of eosinophils
into the lung, whereas eosinophils, in turn, are critical for
the development of airway hyperresponsiveness. In con-
trast, IFN-
 
γ
 
 and IL-4 are not essential for these responses
to RSV infection.
 
23
 
 Futhermore, the same group demon-
strated that IL-5- or IL-4-deficient mice showed markedly
reduced lung eosinophilia and airway hyperresponsive-
ness after RSV infection and allergen exposure.
 
24
 
Interleukin-5 administration during RSV infection restored
responses to allergen in both IL-5- and IL-4-deficient
mice. However, IL-5 administration limited to the sensiti-
zation period restored these responses in IL-4-deficient,
but not IL-5-deficient, animals. Interferon-
 
γ
 
-deficient
mice developed airway hyperresponsiveness and a
degree of lung eosinophilia after allergen exposure
alone; when RSV infection preceded the allergen, these
responses were enhanced.
 
24
 
 These results suggest that
both IL-5, particularly during acute infection, and IL-4 are
critical in mediating the effects of RSV infection, pro-
moting allergic airway sensitization resulting in the
development of airway hyperresponsiveness and lung
eosinophilia.
 
24
 
 The human and mouse data suggest that
eosinophils have a significant role in RSV infection and
RSV-induced asthma.
 
Respiratory syncytial virus activates human 
eosinophils
 
Accumulating evidence demonstrates that RSV can acti-
vate inflammatory cells, such as eosinophils. For exam-
ple, RSV can prime eosinophils for enhanced release of
superoxide anion (O
 
2
 
–
 
) and leukotriene (LT) C
 
4
 
 following
stimulatoin by other agonists.
 
25
 
 Eosinophils also are
susceptible to RSV infection
 
26
 
 and infected eosinophils
release RANTES and macrophage inflammatory protein
(MIP)-1
 
α
 
, both of which are chemotactic factors and
activating factors for eosinophils.
 
27
 
 In our studies, we
demonstrated that RSV adsorbs to eosinophils (M Kato
and H Kimura, unpubl. obs., 2002) within 15 min and
that RSV enhanced eosinophil O
 
2
 
–
 
 production and
 
α
 
M
 
β
 
2 expression by eosinophils in response to the lipid
mediator platelet-activating factor (PAF).
 
28
 
 The exact
mechanism by which RSV primes eosinophil effector
functions remains unknown. However, based on our
studies, we have speculated about how eosinophils are
activated by RSV. The PAF receptor has seven transmem-
brane domains and is thought to be coupled to the
pertussis toxin-sensitive GTP-binding protein (G
 
i
 
-protein).
 
29
 
Platelet-activating factor receptor-mediated stimulation
induces 
 
α
 
M
 
β
 
2 expression on the eosinophil surface, as
well as a conformational change of integrin molecules.
This process represents the so-called ‘inside-out’ signal-
ing, as seen similarly in lymphocytes.
 
30
 
 Once clustering
or multimerization of 
 
α
 
M
 
β
 
2 occurs at the sites of focal
adhesion, the ‘outside-in’ signal is transduced into the
cells.
 
30
 
 Furthermore, this stimulation via 
 
α
 
M
 
β
 
2 increases
production of inositol phosphates and, subsequently,
triggers degranulation of eosinophils.
 
31
 
 In our study,
 
28
 
we demonstrated that adsorption of RSV to eosinophils
enhanced PAF-induced 
 
α
 
M
 
β
 
2 expression and O
 
2
 
–
 
 gen-
eration by eosinophils, which was inhibited by either
agitation to prevent surface adhesion or pretreatment
with anti-CD18. Respiratory syncytial virus may affect the
‘inside-out’ signaling pathway between the PAF receptor
and 
 
α
 
M
 
β
 
2; when eosinophils are stimulated by PAF, RSV
could enhance 
 
α
 
M
 
β
 
2 expression and cellular adhesion
leading to activation followed by O
 
2
 
–
 
 production
(Fig. 3).
Very recently, RSV receptors were reported to represent
a CD14, Toll-like receptor (TLR) 4 and CXC3.
 
32,33
 
However, in our preliminary studies we could not detect
TLR4/CXC3 expression on the eosinophil surface, even
when the cells were cultured with IFN-
 
γ
 
 for 48 h (M Kato
and H Kimura, unpubl. obs., 2002). However, RSV was
demonstrated to bind to the eosinophil surface. The find-
ings indicate that the receptors for RSV on the eosinophil
surface may be other receptors identified previously,
lectin or eosinophil peroxidase (EPO).
 
Respiratory syncytial virus infection induces 
eosinophilic inflammation in epithelial cells
 
Respiratory syncytial virus also contributes to eosinophil
transmigration and activation through upregulation
of  adhesion molecules. For example, RSV induced
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intercellular adhesion molecule (ICAM)-1 expression on
A549 cells and enhanced CD18-dependent eosinophil
adhesion to RSV-infected epithelial cells,
 
34
 
 which repre-
sents an important component of the eosinophil recruit-
ment process.
 
35
 
 Furthermore, when cultured with
RSV-infected A549 cells, eosinophils released signifi-
cant amounts of ECP in a process mediated by CD18;
 
36
 
cellular adhesion mediated by a 
 
β
 
2 integrin is an impor-
tant step in eosinophil activation leading to degranulation
and O
 
2
 
–
 
 production. Respiratory syncytial virus-infected
bronchoepithelial cells produced RANTES and MIP-1
 
α
 
,
resulting in the recruitment of eosinophils and mono-
cytes.
 
37
 
 We also demonstrated that RSV-enhanced O
 
2
 
–
 
generation was strongly inhibited by pretreatment of
cells with anti-CD18 monoclonal antibody.
 
28
 
 In addi-
tion, RSV enhanced PAF-induced eosinophil 
 
α
 
M
 
β
 
2
expression.
 
28 These findings indicate that RSV-infected
epithelial cells contribute to eosinophil activation
through β2 integrin-dependent adhesion in the course of
a lower respiratory tract inflammatory process, such as
bronchiolitis and asthma. Such involvement of eosinophil
adhesion through β2 integrin may be particularly impor-
tant in the pathophysiology of airway inflammation seen
in RSV infection. Our recent results demonstrate that
eosionophil toxic granule proteins, such as major basic
protein (MBP) and EPO, but not ECP or eosinophil-
derived neurotoxin (EDN), synergistically enhanced RSV-
infected epithelilal cell damage and apoptosis (M Kato
and H Kimura, unpubl. obs., 2004). These findings
suggest that eosinophils and their products enhance RSV-
induced airway inflammation in asthma (Fig. 4).
Although the precise mechanism by which RSV infec-
tion exacerbates airway inflammation appears to be fairly
well established, further investigation of these mecha-
nisms could suggest new treatments for patients with RSV
lower respiratory tract infection.
Fig. 3 Model showing intracellular signaling pathways possibly involved in the effect of respiratory syncytial virus (RSV) on human
eosinophils. Respiratory syncytial virus may bind to as yet unidentified RSV receptors on eosinophils. We propose a model of the
effect of RSV on eosinophils in which RSV enhances platelet-activating factor (PAF)-induced O2– generation. The PAF receptor is
coupled to Gi-protein. Platelet-activating factor receptor-mediated stimulation induces αMβ2 (CD11b/CD18, Mac-1) expression
(‘inside-out’ signaling). Once clustering or multimerization of αMβ2 (CD11b/CD18) occurs at the sites of focal adhesion, the ‘out-
side-in’ signal is transduced into the cells. This stimulation via αMβ2 increases production of inositol phosphates and subsequently
triggers degranulation of eosinophils. Respiratory syncytial virus may affect the ‘inside-out’ signaling pathway between the PAF
receptor and αMβ2. Cy, adenylate cyclase; DAG, diacylglycerol; IP3, inositol 1,4,5-trisphosphate; L, ligand; R, receptor; PDE, phos-
phodiesterase; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C; PLC, phospholipase C; PTK, protein tyrosine
kinase; P, phosphorylation; Cbl, the protooncogene c-Cbl.
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Eosinophil products inhibit RSV infection
Although eosinophils may exacerbate RSV-induced
airway inflammation, recent reports suggest that eosi-
nophil products can inhibit RSV infection of HEp-2 cells.
Interestingly, EDN has antiviral activity. Eosinophil-
derived neurotoxin, one of two RNase A-superfamily
ribonucleases, can exert ribonuclease-dependent toxicity
towards extracellular virions of RAV, a single-stranded
RNA virus.38,39 Indeed, our preliminary study demon-
strated that supernatant from activated eosinophils
decreased titers of RSV infecting A549 cells (M Kato and
H Kimura, unpubl. obs., 2003). These findings suggest
that eosinophils may contribute not only to the patho-
physiology of airway inflammation, but also to host
defenses against RSV (Fig. 4).
CONCLUSIONS
Recent reports, including our own results, suggest that
RSV induces eosinophilic inflammation in asthma.
Although the precise mechanism by which RSV infection
exacerbates airway inflammation appears to be emerg-
ing, further investigation of the mechanism may suggest
improved treatments for patients with RSV lower respira-
tory tract infection.
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